Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | SVP & Pres, Neuromodulation | February 28, 2022 | March 02, 2022 |
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,258 |
Ending reported balance
After 2022-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-02-28 · Exercise / conversion · Acquired 1,630 · Balance 177,822 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 2 · 2022-02-28 · Tax withholding · Disposed 564 · Balance 177,258 |
| Deferred Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-28 | Direct | 0 |
Reported balance
After 2022-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-28 · Exercise / conversion · Disposed 1,630 · Balance 0 F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Rani Therapeutics Holdings, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2035-05-27 | Direct | 50,000 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 17:59 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantDirector Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001415889-25-015039 · form4-05302025_090545.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2035-05-27 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-24-137313 · ownership.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,317 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137313 · ownership.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F3 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options. F2 · derivative.exercise_date: The shares subject to the option vested as follows: 1/36th of the shares subject to the option vested monthly over three years from June 17, 2021. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-24-137313 · ownership.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 17:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-24-137313 · ownership.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · price: On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options. Read SEC document |
| May 29, 2024 Filed May 30, 2024 16:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066581 · ownership.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the Company's 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071468 · ownership.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,423 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,423 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071468 · ownership.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,894 Underlying: Class A Common Stock · 15,423 shares Expires 2031-07-28 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F3 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/36th of the shares subject to the option vest monthly over three years from June 17, 2021. F3 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071468 · ownership.xml · derivative · entry 2 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 16:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 101,276 | Not disclosed Strike: $4.11 | Not disclosed |
DisclosureSEC source: 0000950170-23-071468 · ownership.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 08:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 500 | $1.98 | $990.00 |
DisclosureSEC source: 0000950170-23-064982 · ownership.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.97 to $2.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 25, 2023 Filed May 30, 2023 20:09 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 101,276 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001209191-23-033047 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,276 Underlying: Class A Common Stock · 101,276 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| May 25, 2022 Filed May 27, 2022 08:30 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 41,416 | $0.00 Strike: $10.89 | $0.00 |
DisclosureSEC source: 0000899243-22-019858 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,416 Underlying: Class A Common Stock · 41,416 shares Expires 2032-05-24 F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan). Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003865 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,630 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 564 | $44.17 | $24,911.88 |
DisclosureSEC source: 0001225208-22-003865 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,258 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003865 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 11,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003297 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,335 Underlying: Common Stock · 11,335 shares Expires 2023-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. F2 · balance_after: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2023. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003085 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,714 Underlying: Common Stock · 1,714 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 593 | $42.55 | $25,232.15 |
DisclosureSEC source: 0001225208-22-003085 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,192 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003085 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,558 Underlying: Common Stock · 1,779 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 616 | $42.55 | $26,210.80 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,071 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 2,166 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 750 | $42.83 | $32,122.50 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,908 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:46 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002924 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 21,029 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,029 Underlying: Common Stock · 21,029 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 7,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,354 Underlying: Common Stock · 7,354 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 575 | $44.01 | $25,305.75 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,492 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 21:43 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 11,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007638 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 11,017 F1 · kind: Received in kind pro rata distribution from VH Rani, LP. to its limited partners. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 6,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000115 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,175 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,346 | $42.48 | $99,658.08 |
DisclosureSEC source: 0001225208-22-000115 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,406 Read SEC document |
| January 01, 2022 Filed Jan 3, 2022 21:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-000115 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 34,965 | $0.00 Strike: $45.88 | $0.00 |
DisclosureSEC source: 0001225208-21-011122 · doc4.xml · derivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,965 Underlying: Common Stock · 34,965 shares Expires 2031-08-02 F1 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on August 2, 2022, the first anniversary of the date of grant. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 78,192 | $42.59 | $3,330,439.68 |
DisclosureSEC source: 0001225208-21-008788 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,869 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.51 to $42.67, inclusive. The reporting person undertakes to provide upon request by theU.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004223 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 Underlying: Common Stock · 1,629 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 564 | $38.78 | $21,871.92 |
DisclosureSEC source: 0001225208-21-004223 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,061 Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004223 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · derivative · entry 7 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,303 Underlying: Common Stock · 6,303 shares Expires 2022-12-31 F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · shares: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.exercise_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · derivative.expiration_date: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. F5 · balance_after: On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,883 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 652 | $39.20 | $25,558.40 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,996 Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,428 Underlying: Common Stock · 1,713 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 593 | $38.03 | $22,551.79 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,765 Read SEC document |
| February 21, 2021 Filed Feb 23, 2021 22:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003524 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003178 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,337 Underlying: Common Stock · 1,778 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 615 | $37.52 | $23,074.80 |
DisclosureSEC source: 0001225208-21-003178 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,645 Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003178 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.